“In the third quarter we made meaningful progress across our portfolio,” said Elisabet de los Pinos, Ph.D., Chief Executive Officer of Aura. “We are encouraged by the agreement with the FDA under the SPA, as it reinforces the plan for our CoMpass trial and further supports our goal of having the first approved vision-preserving therapy for patients with early-stage choroidal melanoma. The Phase 2 data presented at AAO, with 90% of patients at twelve months follow-up, show results that are highly consistent with, and strongly support, the assumptions for the design of the CoMpass Phase 3 trial.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AURA:
- Insider Trading: Aura Biosciences Stock (NASDAQ:AURA) Bought by Insiders to the Tune of $16M
- Aura Biosciences price target lowered to $20 from $23 at Scotiabank
- Aura Biosciences 11M share Spot Secondary priced at $9.00
- Aura Biosciences announces common stock offering, no amount given
- Aura Biosciences reports agreement from FDA under SPA for CoMpass trial
